Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.73 |
| ▸ | DRD4 | P21917 | 6/20 | 0.73 |
| ▸ | DRD3 | P35462 | 6/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682702 | 0.91 | DRD2 (0.64) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL28770942 | 0.90 | DRD2 (0.62) | DRD2DRD4DRD3ROCK2CCR2 | |
| SCHEMBL4827267 | 0.88 | DRD2 (0.60) | DRD2DRD4DRD3SIGMAR1PARP2 | |
| SCHEMBL8796920 | 0.88 | DRD2 (0.60) | DRD2DRD4DRD3SIGMAR1CCR2 | |
| SCHEMBL260734 | 0.86 | DRD2 (0.63) | DRD2DRD4DRD3ALOX15 | |
| SCHEMBL7481395 | 0.86 | DRD2 (0.58) | DRD2DRD4DRD3SIGMAR1CCR2 | |
| SCHEMBL14375224 | 0.83 | DRD2 (0.55) | DRD2DRD4DRD3SIGMAR1PARP2 | |
| SCHEMBL31370877 | 0.82 | DRD4 (0.75) | DRD2DRD4DRD3PARP1HTR1A | |
| SCHEMBL6701280 | 0.82 | DRD4 (0.75) | DRD2DRD4DRD3ALOX15HTR1A | |
| SCHEMBL6694947 | 0.80 | DRD2 (0.64) | DRD2DRD4DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610641-B2 | Transition metal complex | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-08-26 | — | — | US | claimed |
| US-20020010120-A1 | Composition and method for bleaching a substrate | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | claimed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | claimed |
| EP-1689384-A4 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | CONCAT LP (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2011501-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use | Chelator LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1261349-B1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CHELATOR LLC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1499702-B1 | DETERGENT COMPOSITIONS AND COMPONENTS THEREOF | PROCTER & GAMBLE (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1689384-A1 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | Concat LP (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005053674-A1 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | CONCAT LP (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | CONCAT LP, A CALIFORNIA LIMITED PARTNERSHIP (US) | 2005-05-26 | — | — | US | disclosed |
| US-6881732-B2 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CHELATOR LLC (US) | 2005-04-19 | — | — | US | disclosed |
| US-6387891-B2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN COSMETICS AND PERSONAL CARE PRODUCTS, INHIBITION OF METALLOENZYMES, AND INHIBITION OF REPERFUSION INJURY | CONCAT, LTD. | 2002-05-14 | — | — | US | disclosed |
| US-20020010120-A1 | Composition and method for bleaching a substrate | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | disclosed |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | CHELATOR LLC | 2001-11-15 | — | — | US | disclosed |
| US-6264966-B1 | DEODORANTS; THERAPY FOR ORAL DISEASES | CONCAT, LTD. | 2001-07-24 | — | — | US | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | MPO, LPO, SOD1 | DRD2 3746/4885DRD4 3247/4885DRD3 3139/4885 |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | SLC39A14, CHIA, CA2 | DRD2 4820/4885DRD4 4806/4885DRD3 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.